TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 177 filers reported holding TG THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $53,681,000 | -70.0% | 5,645 | +5.2% | 0.02% | -65.1% |
Q3 2021 | $178,641,000 | -48.3% | 5,368 | -39.9% | 0.04% | -44.9% |
Q2 2021 | $345,622,000 | -19.7% | 8,931 | 0.0% | 0.08% | -36.6% |
Q1 2021 | $430,455,000 | -28.6% | 8,931 | -22.9% | 0.12% | -30.5% |
Q4 2020 | $602,468,000 | +118.7% | 11,582 | +12.5% | 0.18% | +121.2% |
Q3 2020 | $275,452,000 | -3.0% | 10,294 | -29.4% | 0.08% | +5.3% |
Q2 2020 | $283,999,000 | +56.5% | 14,580 | -20.9% | 0.08% | +49.0% |
Q1 2020 | $181,422,000 | +2859.1% | 18,438 | +4138.6% | 0.05% | +5000.0% |
Q4 2019 | $6,131,000 | +151.1% | 435 | 0.0% | 0.00% | – |
Q3 2019 | $2,442,000 | -35.1% | 435 | 0.0% | 0.00% | -100.0% |
Q2 2019 | $3,761,000 | +7.6% | 435 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $3,496,000 | +96.1% | 435 | 0.0% | 0.00% | – |
Q4 2018 | $1,783,000 | -32.5% | 435 | 0.0% | 0.00% | – |
Q3 2018 | $2,642,000 | -98.0% | 435 | -95.6% | 0.00% | -100.0% |
Q2 2018 | $132,211,000 | -5.0% | 9,834 | 0.0% | 0.02% | -21.4% |
Q1 2018 | $139,098,000 | – | 9,834 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 1,890,000 | $15,800,400 | 5.14% |
Ghost Tree Capital, LLC | 1,000,000 | $8,360,000 | 2.75% |
Soleus Capital Management, L.P. | 2,884,382 | $24,113,434 | 2.22% |
M28 Capital Management LP | 216,600 | $1,810,776 | 2.08% |
Paradigm Biocapital Advisors LP | 3,619,015 | $30,254,965 | 2.05% |
683 Capital Management, LLC | 1,350,000 | $11,286,000 | 0.88% |
Parkwood LLC | 165,414 | $6,081 | 0.66% |
Spotlight Asset Group, Inc. | 79,000 | $660,440 | 0.60% |
Pier Capital, LLC | 392,709 | $3,283,047 | 0.53% |
Quantum Private Wealth, LLC | 91,081 | $761,438 | 0.36% |